Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The levels of kynurenic acid (KYNA), an astrocyte-derived metabolite of the branched kynurenine pathway (KP) of tryptophan degradation and antagonist of α7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, are elevated in the prefrontal cortex (PFC) of individuals with schizophrenia (SZ). Because endogenous KYNA modulates extracellular glutamate and acetylcholine levels in the PFC, these increases may be pathophysiologically significant. Using brain tissue from SZ patients and matched controls, we now measured the activity of several KP enzymes (kynurenine 3-monooxygenase [KMO], kynureninase, 3-hydroxyanthranilic acid dioxygenase [3-HAO], quinolinic acid phosphoribosyltransferase [QPRT], and kynurenine aminotransferase II [KAT II]) in the PFC, ie, Brodmann areas (BA) 9 and 10. Compared with controls, the activities of KMO (in BA 9 and 10) and 3-HAO (in BA 9) were significantly reduced in SZ, though there were no significant differences between patients and controls in kynureninase, QPRT, and KAT II. In the same samples, we also confirmed the increase in the tissue levels of KYNA in SZ. As examined in rats treated chronically with the antipsychotic drug risperidone, the observed biochemical changes were not secondary to medication. A persistent reduction in KMO activity may have a particular bearing on pathology because it may signify a shift of KP metabolism toward enhanced KYNA synthesis. The present results further support the hypothesis that the normalization of cortical KP metabolism may constitute an effective new treatment strategy in SZ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Common regions of the human frontal lobe recruited by diverse cognitive demands
Duncan, J., & Owen, A. M. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01633-7 · Cited by 2,498
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 859
Self-citationKessler, M., Terramani, T., Lynch, G., & Baudry, M. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb01881.x · Cited by 739
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Self-citationvan Berckel, B. N., Bossong, M. G., Boellaard, R., Kloet, R., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities
Schwarcz, R., & Pellicciari, R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034439 · Cited by 556
Self-citationKynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 538
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Prefrontal Serotonin Depletion Affects Reversal Learning But Not Attentional Set Shifting
Clarke, H. F., Walker, S. C., Crofts, H. S., Dalley, J. W., Robbins, T. W., & Roberts, A. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3690-04.2005 · Cited by 358
Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics
Radewicz, K., Garey, L. J., Gentleman, S. M., & Reynolds, R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.137 · Cited by 342
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M.-L., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq086 · Cited by 325
Characterization of the Kynurenine Pathway in Human Neurons
Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 324
Okuda, S., Nishiyama, N., Saito, H., & Katsuki, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12553 · Cited by 301
Prenatal Nutritional Deficiency and Risk of Adult Schizophrenia
Brown, A. S., & Susser, E. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn096 · Cited by 289
Quinolinic acid is a potent lipid peroxidant in rat brain homogenates
Rios, C., & Santamaria, A. (1991) · Neurochemical Research · doi:10.1007/bf00966592 · Cited by 271
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm069 · Cited by 266
Prefrontal Activation Deficits During Episodic Memory in Schizophrenia
Ragland, J. D., Laird, A. R., Ranganath, C., Blumenfeld, R. S., Gonzales, S. M., & Glahn, D. C. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08091307 · Cited by 250
Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia
Eisenberg, D. P., & Berman, K. F. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.111 · Cited by 246
Structure, expression, and function of kynurenine aminotransferases in human and rodent brains
Han, Q., Cai, T., Tagle, D. A., & Li, J. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0166-4 · Cited by 239
Characterization of rat brain kynurenine aminotransferases I and II
Guidetti, P., Okuno, E., & Schwarcz, R. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19971101)50:3<457::aid-jnr12>3.0.co;2-3 · Cited by 233
Self-citationMiller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., & Weis, S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.015 · Cited by 233
Potter, M. C., Elmer, G. I., Bergeron, R., Albuquerque, E. X., Guidetti, P., Wu, H.-Q., & Schwarcz, R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.39 · Cited by 228
Self-citationElevations of Endogenous Kynurenic Acid Produce Spatial Working Memory Deficits
Chess, A. C., Simoni, M. K., Alling, T. E., & Bucci, D. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl033 · Cited by 225
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission
MÜller, N., & Schwarz, M. (2006) · Neurotoxicity Research · doi:10.1007/bf03033242 · Cited by 214
Röver, S., Cesura, A. M., Huguenin, P., Kettler, R., & Szente, A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970467t · Cited by 211
Goldstein, L. E., Leopold, M. C., Huang, X., Atwood, C. S., Saunders, A. J., Hartshorn, M., Lim, J. T., Faget, K. Y., Muffat, J. A., Scarpa, R. C., et al. (2000) · Biochemistry · doi:10.1021/bi992997s · Cited by 211
Cortical Kynurenine Pathway Metabolism: A Novel Target for Cognitive Enhancement in Schizophrenia
Wonodi, I., & Schwarcz, R. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq002 · Cited by 190
Self-citationGlial cells in schizophrenia: pathophysiological significance and possible consequences for therapy
Bernstein, H.-G., Steiner, J., & Bogerts, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.59 · Cited by 189
Endogenous kynurenic acid disrupts prepulse inhibition
Erhardt, S., Schwieler, L., Emanuelsson, C., & Geyer, M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.006 · Cited by 178
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease
Schwarcz, R., Guidetti, P., Sathyasaikumar, K. V., & Muchowski, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.005 · Cited by 176
Self-citationThe kynurenic acid hypothesis of schizophrenia
Erhardt, S., Schwieler, L., Nilsson, L., Linderholm, K., & Engberg, G. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.025 · Cited by 175
Executive Functioning Component Mechanisms and Schizophrenia
Kerns, J. G., Nuechterlein, K. H., Braver, T. S., & Barch, D. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.027 · Cited by 162
Deconstructing Psychosis With Human Brain Imaging
Gur, R. E., Keshavan, M. S., & Lawrie, S. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm045 · Cited by 159
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo
Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y., & Schwarcz, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05893.x · Cited by 150
Self-citationWu, H.-Q., Pereira, E. F. R., Bruno, J. P., Pellicciari, R., Albuquerque, E. X., & Schwarcz, R. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9235-2 · Cited by 146
Self-citationShepard, P. D., Joy, B., Prendeville, L. C., & Schwarcz, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300188 · Cited by 140
Self-citationMatute, C., Melone, M., Vallejo‐Illarramendi, A., & Conti, F. (2005) · Glia · doi:10.1002/glia.20119 · Cited by 129
Synthesis of Quinolinic Acid by 3‐Hydroxyanthranilic Acid Oxygenase in Rat Brain Tissue In Vitro
Foster, A. C., White, R. J., & Schwarcz, R. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb02826.x · Cited by 126
Self-citationAstrocyte‐derived kynurenic acid modulates basal and evoked cortical acetylcholine release
Zmarowski, A., Wu, H. ‐., Brooks, J. M., Potter, M. C., Pellicciari, R., Schwarcz, R., & Bruno, J. P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06594.x · Cited by 122
Self-citationChess, A. C., Landers, A., & Bucci, D. J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.013 · Cited by 121
Steiner, J., Bernstein, H., Bielau, H., Farkas, N., Winter, J., Dobrowolny, H., Brisch, R., Gos, T., Mawrin, C., Myint, A.-M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.001 · Cited by 106
Dykens, J. A., Sullivan, S. G., & Stern, A. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90691-5 · Cited by 99
Konradsson-Geuken, Å., Wu, H. Q., Gash, C. R., Alexander, K. S., Campbell, A., Sozeri, Y., Pellicciari, R., Schwarcz, R., & Bruno, J. P. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.052 · Cited by 93
Self-citationWang, Y., Lawson, M. A., Dantzer, R., & Kelley, K. W. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.06.152 · Cited by 88
Foster, A. C., Whetsell, W. O., Bird, E. D., & Schwarcz, R. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90647-x · Cited by 83
Self-citationAlterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder
Miller, C. L., Llenos, I. C., Cwik, M. F., Walkup, J. T., & Weis, S. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.01.013 · Cited by 82
Lewis, D. A., Hashimoto, T., & Morris, H. M. (2008) · Neurotoxicity Research · doi:10.1007/bf03033813 · Cited by 80
Heyes, M. P., & Quearry, B. J. (1988) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83925-0 · Cited by 77
Nicotinic Agonists and Psychosis
Simosky, J., Stevens, K., & Freedman, R. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007024606168 · Cited by 75
Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics.
Wierzba‐Bobrowicz, T., Lewandowska, E., Kosno-Kruszewska, E., Lechowicz, W., Pasennik, E., & Schmidt-Sidor, B. (2004) · PubMed · Cited by 65
Foster, R., Kandanearatchi, A., Beasley, C., Williams, B., Khan, N., Fagerhol, M. K., & Everall, I. P. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05219.x · Cited by 63
Effects of risperidone on glutamate receptor subtypes in developing rat brain
Choi, Y. K., Gardner, M. P., & Tarazi, F. I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.010 · Cited by 62
Radical Scavenging Properties of Tryptophan Metabolites
Goda, K., Hamane, Y., KISHIMOTO, R., & Ogishi, Y. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4709-9_50 · Cited by 61
Hardeland, R., Zsizsik, B. K., Pöeggeler, B., Fuhrberg, B., Holst, S., & Coto‐Montes, A. M. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4709-9_49 · Cited by 59
Pakkenberg, B., Scheel‐Krüger, J., & Kristiansen, L. V. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01447.x · Cited by 53
Ido (indolamine 2,3-dioxygenase) Expression and Function in the CNS
Kwidzinski, E., Bunse, J., Kovac, A. D., Ullrich, O., Zipp, F., Nitsch, R., & Bechmann, I. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_13 · Cited by 51
Aoyama, N., Takahashi, N., Saito, S., Maeno, N., Ishihara, R., Ji, X., Miura, H., Ikeda, M., Suzuki, T., Kitajima, T., et al. (2006) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2006.00231.x · Cited by 46
Potential Noradrenergic Targets for Cognitive Enhancement in Schizophrenia
Friedman, J. I., Stewart, D. G., & Gorman, J. M. (2004) · CNS Spectrums · doi:10.1017/s1092852900009330 · Cited by 41
ROEVER, S., CESURA, A. M., HUGUENIN, P., KETTLER, R., & SZENTE, A. (1998) · ChemInform · doi:10.1002/chin.199820156 · Cited by 34
Effects of oxygen on 3-hydroxyanthranilate oxidase of the kynurenine pathway
Dang, Y., Xia, C., & Brown, O. R. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00136-1 · Cited by 17
Cited by
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationInflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Müller, N. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby024 · Cited by 648
The role of inflammation in schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00372 · Cited by 465
Wang, A. K., & Miller, B. J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx035 · Cited by 389
Metadata
- Authors
- Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-29
- Volume
- 37
- Issue
- 6
- Pages
- 1147-1156
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2139194458
- Cited by
- 253
- References
- 64
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.